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RATIONALE FOR UNDERTAKING THIS STUDY: 
 Essential hypertension is a multi-factorial disease caused by 
interactions between an individual’s genetic makeup and the ambient 
environment. A personalized  pharmacogenomic approach to uncover 
possible potential benefits of existent pharmacotherapeutic intervention is 
a novel and needed approach in Hypertension management. 
 Abnormalities of membrane sodium transport in the kidney play an 
important role in hypertension. Alpha-adducin (ADD-1) is a ubiquitously 
expressed cytoskeletal protein that appears to be involved in the distal 
tublular sodium  ion transport in the nephrons. Cusi et al. reported that the 
Gly460Trp polymorphism of ADD-1 was associated with a salt-sensitive 
form of hypertension. Salt sensitive forms of essential hypertension, i.e., 
carriers of 460Trp variant showed a greater fall in mean arterial BP than 
Gly460Gly homozygous wild type carriers after hydrochlorothiazide 
treatment in Caucasians.  
 Hydrochlorthiazide is a 1st line anti hypertensive agent 
recommended by JNC8 (2013-14) recommendations for management of 
Hypertension. Identification of genetic influence of Adducin-1 
polymorphism can serve to identify thiazide sensitive patients in the 
initial stage of disease, making way for a personalised and 
Pharmacoeconomic solution for both the patients and the Health care 
system. 
  However, subsequent study results have been inconsistent. Very 
few studies have been reported worldwide about its relation to 
hypertension. Therefore, this study was undertaken to examine whether 
the Gly460Trp polymorphism of ADD-1 was associated with essential 
hypertension and its effect on responsiveness to hydrochlorthiazide in our 
population. 
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ABSTRACT 
INTRODUCTION: 
 Essential hypertension is a complex polygenic inherited disorder. 
Abnormalities of membrane sodium transport in the kidney play an important 
role in hypertension. Alpha-adducin (ADD-1) is a ubiquitously expressed 
cytoskeletal protein that appears to be involved in the distal tublular sodium  ion 
transport in the nephrons. Cusi et al. reported that the Gly460Trp polymorphism 
of ADD-1 showed a greater fall in mean arterial pressure than Gly460Gly 
homozygous wild type carriers after hydrochlorothiazide treatment in 
Caucasians.  
 However, subsequent study results have been inconsistent. Very few 
studies have been reported worldwide about its relation to hypertension. 
Therefore, this study was undertaken to examine whether the Gly460Trp 
polymorphism of ADD-1 was associated with essential hypertension and its 
effect on responsiveness to hydrochlorthiazide in our population. 
METHODOLOGY: 
 This study was conducted in the Hypertension Out-patient clinic of 
Government Kilpauk Medical College during the period of June, 2014 to June, 
2015 after obtaining permission from the IEC, GKMC. Open labeled, stratified 
randomized, parallel assignment, interventional safety and efficacy study of  
T.Hydrochlorthiazide 12.5mg  once/day as an add on therapy in uncontrolled 
(BP >140/90mmHg) Essential Hypertension with post hoc Genotyping of ADD-
1 Gly460Trp by tetra-ARMS PCR assay was carried out among 100 Essential 
Hypertension patients. 
RESULTS & CONCLUSION: 
 Three genotype classes were identified in our population: Gly460Gly 
(Homozygous), Gly460Trp (Heterozygous) and Negative (neither Homozygous 
nor Heterozygous).The prevalence of ADD-1 Gly460Trp mutation in our study 
group was 13%. Gly460Trp carriers showed significant linkage with higher 
staging of Essential Hypertension in spite of more than one class of pharmaco-
therapeutic intervention.  
 Irrespective of genotypic variations in ADD-1, Hydrochlorthiazide 12.5mg 
once/day addition to the other class of antihypertensive agents produced 
additive antihypertensive efficacy of the regimes used. Gly460Trp was a low 
frequency genotype trait and did not show statistically different endpoint result 
variations in comparison to the other 2 genotypes (Gly460Gly & Negative) in 
our study. 
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INTRODUCTION 
 Essential hypertension (EH) is a typical example of an “iceberg” 
disease. A substantial proportion of the general population remain below 
the waterline with regards to diagnosis and adequate treatment. In spite of 
being an under reported and inadequately treated disease, its prevalence 
among 35-70 year old Indians is reported to be about 30.7%.[1] 
Hypertension causes 8.75% of annual mortal events in India, i.e., about 
1.07 million deaths per year.[2] 
 Essential hypertension (EH) is a polygenic hereditary disease and 
its phenotypic expression is influenced by lifestyle and environmental 
factors. These lifestyle and environmental factors include an individual’s 
dietary hygiene (daily salt intake, saturated fat and dietary fibre 
consumption), level of physical fitness, alcohol intake and tolerability to 
psychosocial stress. Most of these lifestyle and environmental factors are 
grouped under modifiable risk factors. 
 While titration of blood pressure is possible by positively 
controlling an individual’s modifiable risk factors by means of health 
promoting non-pharmacological interventions, the inherent genetic risk of 
development and propagation of hypertension and its complications 
remains non-modifiable. 
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 Renal handling of sodium salt has been ascertained to play a key 
role in the disease process. Any insult that impairs the physiological 
sodium balance in the body, either by affecting sodium retention or 
excretion reflects on the blood pressure of an individual.  
Three mechanisms have been postulated to explain the renal mediated 
alterations in the internal sodium milieu.[3] 
1. Limited sodium excretion due to a reduced Glomerular Filtration 
Rate 
2. Any hormonal (e.g.: Angiotensin II, Aldosterone, Vasopressin, 
Endogenous Ouabain, Dopamine,etc)  or genetic disorder that 
promotes sodium reabsorption in  the distal nephrons 
3. Renal ischemia, Oxidative stress and inflammation  
 
Sodium is the major extracellular cation in the body. Increased retention 
of sodium salt results in an expansion of the extracellular fluid volume 
(ECFV). This expansion in ECFV results in structural and functional 
adaptations in the Heart, Brain, Kidney and Peripheral arteries. 
Hypertension is considered as an independent predisposing risk factor for 
congestive cardiac failure, coronary artery disease, cerebro-vascular 
accidents, renal dysfunction and peripheral arterial disease.[4] 
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 Understanding the complexity of its etio-pathogenesis, makes the 
pharmacotherapy of EH simpler. Major classes of antihypertensive agents 
that are used in clinical practice can be broadly classified into: 
I. Diuretics : Thiazide/ Loop/ K+ sparing agents 
II. Sympatholytics: α-Blockers/ β-Blockers/ Mixed α&β-
Blockers/Central α2 agonists 
III. Vasodilators: Calcium Channel Blockers/ K+ Channel Openers/ 
Direct arterial vasodilator/ Mixed arterial & venous dilator 
IV. Renin Angiotensin system blockers: Direct Renin Inhibitors/ 
Angiotensin Converting Enzyme Inhibitors/ Angiotensin 1 
Receptor Blockers/ Aldosterone antagonist 
 
Most antihypertensive agents modulate blood pressure by interfering with 
the determinants of blood pressure.[5]  
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For the effective arrest of disease progression and complications, the 
current treatment guidelines as per Joint National Committee 8 (JNC 8) 
recommends initiation of pharmacotherapy in patients < 60 years to 
achieve blood pressure goals of Systolic/Diastolic BP <140/90mmHg.[6]   
 
Fig.1: Drugs modulate determinants of Blood pressure and modulate Blood Pressure.  
(Adapted f om Principl s of Pharmacology by David E.Golam 
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Though a wide array of drug moieties are available, their extent of 
lowering blood pressure remains highly unpredictable. Evidence based 
JNC8 guidelines recommends the administration of thiazide diuretics / 
Angiotensin Converting Enzyme inhibitors/ Angiotensin Receptor 
Blockers(ACEi/ARBs) / Calcium Channel Blockers(CCBs), either 
combined or alone as the first line antihypertensive agents. But, ethnic 
and inter-individual variability in pharmacological response is seen with 
all the first line drugs.[7] 
 Dose- response relationship of antihypertensive agents follow 
either linear (adrenergic receptor blockers and CCBs) or non-linear 
patterns(ACEi/ARBs).[8] So in order to titrate the blood pressure 
Fig. 2: JNC 8 guidelines in management of Hypertension. 
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throughout a 24 hour period, an appropriate drug at the right dose and 
correct dosing regimen should be customised for each patient. This 
rational pharmaco-therapeutic approach is further challenged by the 
possible Pharmacokinetic/ Pharmacodynamic drug interactions due to 
other co-administered drugs, especially in geriatric population with 
polypharmacy. 
 Furthermore, the mapping of the human genome, genetic predictors 
especially single nucleotide polymorphisms have been identified as 
potential targets for affecting drug response.[9]  SNPs involving Renin 
Angiotensin Aldosterone system, Adrenoceptors, Renal epithelial solute 
transporters have been brought to light.[10] Hence the concept of 
“Personalised Medicine”- Using knowledge of an individual’s genetic 
profile to guide therapeutic decisions in diagnosis, treatment and 
prevention seems to be a clinching approach. 
 Adducin is a ubiquitously present tetrameric cytoskeletal protein 
made up of an α and either a β/γ heterodimeric subunits. It is coded by 3 
genes ADD-1(α), ADD-2(β) and ADD-3(γ). It is involved in inter-cellular 
contact, signal transduction and cell membrane ionic transport. By means 
of positional cloning, α Adducin has been mapped at chromosome 
4p16.3[11]  In rats and humans, a SNP(Gly460Trp polymorphism) in α-
Adducin leads to stimulation of Na+/K+-ATPase activity in renal tubular 
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cells resulting in increased sodium reabsorption and hence salt sensitive 
form of EH.[12] 
In salt sensitive forms of EH in Caucasoid ethnic groups,  carriers 
of Gly460Trp genotype variant showed a greater response (i.e., fall in 
Mean Arterial BP) when treated with hydrochlorthiazide  than their 
counterparts with Gly460Gly homozygous wild type carriers.[13]  
However, subsequent study results have been inconsistent. Very few 
studies have been reported worldwide to establish association of ADD-
1Single nucleotide polymorphism and Hydrochlorthiazide (HCTZ) 
responsiveness in Essential hypertension. Therefore, we have planned to 
determine whether the Gly460Trp polymorphism of ADD-1 was 
associated with EH and its effect on responsiveness to HCTZ in our 
population. 
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AIM OF THE STUDY 
Single nucleotide polymorphism involving the α-Adducin gene (ADD-1) 
has been identified as a possible genetic marker for the prevention, 
diagnosis and treatment of Essential Hypertension. Gly460Trp 
polymorphism of ADD-1 gene is associated with salt-sensitive form of 
hypertension, more amenable for treatment with thiazide diuretics due to 
augmented blockage of renal tubular sodium reabsorption. 
With the basis of this hypothesis, the current study was undertaken with 
the following Aim:  
1. To find the prevalence of  ߙ-Adducin polymorphism in patients 
with essential hypertension  
2. To find if an association exists between ADD-1 Gly460Trp 
polymorphism and stage of Blood pressure control in subjects 
with their existing drug treatment   
3. To assess the responsiveness to Hydrochlorthiazide 12.5mg 
Once daily (as an add on agent) among patients with poor 
response to their current antihypertensive treatment  
4. To ascertain/ refute ߙ-Adducin polymorphism mediated 
hydrochlorthiazide responsiveness among the subjects. 
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REVIEW OF LITERATURE 
THIAZIDE DIURETIC AS AN ANTIHYPERTENSIVE AGENT -  
A PAST TO PRESENT PERSPECTIVE: 
 The modern era of antihypertensive drug therapy began with the 
break through discovery of an orally effective diuretic - Chlorthiazide by 
Beyer and Sprague in 1958.[14] The drug was synthesised by chemical 
modification of sufonamide compounds in search of diuretics with 
Carbonic Anhydrase inhibiting property. Serendipitously, the drug was 
recognised as a blood pressure lowering agent when it was used in 
patients with congestive heart failure.[15]  
 Following this observation, Clinical trials were undertaken 
simultaneously by two separate groups of researchers: Freis et.al and 
Beam et.al. Clinical experience by these pioneer researchers, proposed 
that the drug was equally effective and better accepted by hypertensive 
patients than a strict salt restricted diet.[16] Thiazide, when used in 
combination with the other classes of antihypertensive agents was also 
found to enhance their efficacy, down titrate the dosage required and 
ameliorate toxicity. Hence thiazide diuretics were published as adjunctive 
agents in management of hypertension in the mid 19th century [17]   
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 Veterans Cooperative study, conducted in 1964, was a landmark 
randomised controlled clinical trial in the history of hypertension 
management. This trial established a superior survival benefit attributed 
by a cocktail of thiazide diuretic, reserpine and hydralazine among 
moderate to severe hypertensive patients.[18] 
 Subsequently, many clinical trials were undertaken to confirm the 
efficacy of thiazide diuretics as an antihypertensive agents. But all these 
trials recorded a reduction in diastolic blood pressure as the primary end 
point and concluded that a reduction of DBP by thiazide based cocktail of 
drugs produces cardiovascular survival benefit.[19] 
 So, clinical trials concentrating on reduction of Systolic Blood 
Pressure were undertaken, namely – SHEP (Systolic Hypertension in the 
Elderly Program) and ALLHAT (Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial). The ALLHAT trial was the 
largest RCT on hypertension management, and it compared the efficacy 
of initiation therapy with the various available antihypertensives on 
cardiovascular survival benefit.[20] 
 Combining results from these above trials, thiazide diuretics were 
recommended as first choice treatment for hypertension in the Seventh 
Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7)[21] 
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CURRENT STATUS OF THIAZIDE DIURETIC IN 
HYPERTENSION MANAGEMENT AMONG INDIAN 
POPULATION: 
 The antihypertensive pipeline has remarkably expanded over the 
last 60 years. Currently an appropriate Pharmaco-therapeutic intervention 
could be selected rationally from the abundant armamentarium of 
different classes of antihypertensive drugs available.  
 
 
 The antihypertensive pipeline has evolved rapidly, probably with 
the understanding of various facets of hypertension pathophysiology and 
improvements in the field of science and technology. With this better 
Fig.3: Timeline of discovery of Antihypertensive classes of drugs 
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outlook on the disease process, different classes of pharmacological 
agents have been discovered and successfully used in clinical practice. 
The paramount role played by thiazide diuretics as one of the first step 
agent in the management of Hypertension still holds good to current date. 
The general schema for management of hypertension, according to JNC 8 
recommendations is as follows: 
 
 Incorporating these recommendations to our Indian subpopulation, the 
following generalisations and dictums have been put to practice: 
1. South Asian general population respond to antihypertensive 
management in a similar fashion like Caucasian population.[22] 
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2. Diuretics are first line agents in the management of hypertension in 
general population unless there is an absolute or relative 
contraindication to the specific drug per se.[23] 
3. The 2011 update on hypertension management released by the 
National Institute of Health and Clinical Excellence (NICE) in 
India also Thiazide diuretics as first step pharmacotherapeutic 
agents, since they confer cardiovascular survival benefit.[24,25] 
4. All the landmark studies establishing Thiazide diuretic as first step 
agent was conducted using Chlorthalidone. Effectively Equivalent 
dose of Hydrochlorthiazide (HCTZ) has been established from 
various studies. 25mg Clorthalidone = 50mg HCTZ. [26] 
5. Among the Thiazide like diuretics, Hydrochlorthiazide is the most 
available and extensively used agent in India.[25] 
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UNDERSTANDING HCTZ AS AN ANTIHYPERTENSIVE 
AGENT: 
 Hydrochlorthiazide is a prototype member of thiazide class of 
diuretics. Its chemical formula is C7H8ClN3O4S2 [27] 
ATC Code Name DDD 
Route of 
administration 
C03AA03 Hydrochlorthiazide 25mg Oral 
 
 
 
  
Fig.4: 2-D structure of Hydrochlorthiazide 
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Pharmacokinetic parameters: 
Absorption 50-60% biovailability with orally administered tablet 
formulations 
Distribution Vd – Not available 
Protein binding : 67.9%  
Metabolism Not metabolised 
Elimination Renal elimination 
Does not cross blood brain barrier. Crosses placental 
barrier. Excretion in milk (+) 
Half life  5.6 – 14.8 hours 
 
Recognised targets of drug action: 
 Inhibitor at Solute carrier family 12 member 3 – Na+/Cl- 
cotransporter [28] 
 Inhibition of carbonic anhydrase type- 1,2,4,9,12  [29] 
 Unknown action on Calcium-activated potassium channel subunit 
alpha-1[30] 
Mechanism and site of action: 
 Micropuncture and in situ microperfusion studies have clearly 
demonstrated that HCTZ exerts its diuretic action by inhibiting  Na+/Cl- 
cotransporter protein (NCC; gene symbol SLC12A3) in the distal 
convoluted tubules.[31] 
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 The NCC reabsorbs Na+ from the distal convoluted tubules (DCT) 
back into the interstitium and accounts for approximately 7% of total 
sodium reabsorption.[32] Under normal conditions, the NCC transports 
sodium and chloride from the tubular lumen into the epithelial cell lining 
of the DCT. This energy dependant process is supported by the sodium 
gradient established by Na+/K+ATPase activity in the basolateral 
membrane. 
  Since Thiazide diuretics inhibit the NCC, they decrease sodium 
reabsorption and increase fluid loss in urine. This volume loss through 
urine, helps in clearing off excess ECFV and Plasma volume, especially 
in volume overloaded conditions.  
Fig.5: Mechanism of Action of HCTZ 
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 Volume loss also causes decrease in venous return, increase in 
renin release, reduction in cardiac output and reduction in blood 
pressure.[33] An acute transient effect of increase in total peripheral 
resistance within a few days of administration of Thiazide is noticed. This 
is due to compensatory release of sympathetic nervous system and renin-
angiotensin- aldosterone system in response to the decrease in Cardiac 
Output.[34] 
 But on chronic administration of Thiazide diuretics, blood pressure 
reduction occurs in spite of full recovery of ECFV within 4-6weeks of 
Thiazide initiation.[35]  If the antihypertensive effect of Thiazide diuretics 
is due to its diuretic/sodium depletion action alone, then loop diuretics 
should have superior blood pressure lowering efficacy. But in real time 
scenario, loop diuretics do not reduce blood pressure to the degree of 
Thiazide class of drugs.[36]  
 Hence the exact mechanism of blood pressure lowering of thiazides 
is probably not thru its diuretic/sodium depleting activity alone. Other 
probable mechanisms to explain the antihypertensive property of 
thiazides have been put forth, but still stands to be fully validated and 
understood.The hypothesis of the ‘vasodilator theory’, which highlights 
the response following the decrease in total peripheral resistance with 
Thiazide class of diuretics.[37] 
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 Hence to uncover the exact antihypertensive property of Thiazide 
class of drugs, a more comprehensive and multifaceted approach to 
hypertension research was needed and undertaken. 
PHARMACOGENOMICS OF HYPERTENSION – CAN 
THIAZIDE RESPONSIVENESS BE GUIDED BY ONE’S GENES? 
Genetic basis of Essential Hypertension susceptibility was estimated to be 
30-70%. Uncovering of these gene foci could productively enhance the 
development of new chemical moieties for better care and benefit of the 
patient. 
Fig.6: Theoretical hypothesis explaining thiazide’s antihypertensive action 
on chronic use via modulation of total peripheral resistance 
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 The genetic markers for salt sensitive forms of Essential 
Hypertension predilection, to name a few are: single nucleotide 
polymorphism (SNP) involving Angiotensin gene, alpha adducin 
(ADD1), the G-protein beta-3 subunit gene (GNB3) and the aldosterone 
synthase gene.[38] 
 
 
 
The Thiazide sensitive NCC has a pivotal role in the treatment of 
hypertension, since Thiazide class of diuretics have been affirmed as the 
first line antihypertensive agent. The gene coding for this Na+/Cl- 
cotransporter (SLC12A3) was identified as a potential target in the 
antihypertensive agents pipeline.[39] Since this scientific fact was 
established, research to uncover the genetic basis of Thiazide action has 
been rigorously pursued. 
Fig.7: Genetic predictors of Hypertesion and  
potential pharmacogenetic targets of drug action. 
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 Based on large scale Genome wide Linkage study, many candidate 
genes were uncovered as potential influencers of HCTZ responsiveness. 
Pharmacogenetic markers of HCTZ responsiveness that gained lot of 
research perusal are represented in the table below. 
  
GENE NAME 
GENETIC 
POLYMORPHISM 
IDENTIFIED 
FUNCTION ALTERED 
α-Adducin  ADD1_rs4963  
ADD1A_rs4961 
Increased renal tubular 
reabsorption of sodium 
ion  through activation of 
Na/K-ATPase 
Endothelial Nitric 
Oxide(NO) 
synthase  
 
ENOSA_rs1799983  Regulates amount of NO 
in blood 
 
G protein, β3 
 
GNB3_rs6489738 Mediates signal 
transduction across cell 
membranes 
 
Sodium channel, 
gamma-subunit 
promotor  
 
SCNN1G_rs5729  
SCNN1G_rs5723  
SCNN1G_rs7200183  
SCNN1G_hcv11894753 
Modulated transepithelial 
Na+ transport 
 
Sodium channel, 
nonvoltage-gated 
1, beta  
SCNN1B_rs250563 Modulates transepithelial 
Na+  transport 
 
Solute carrier 
family 12 Na +/Cl 
– transporters  
 
SLC12A3_hcv9609124  
SLC12A1_rs1552311 
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α-ADDUCIN GENE TARGET– HCTZ ANTIHYPERTENSIVE 
EFFICACY – POTENTIAL LEADS UNCOVERED: 
 Over the recent years, a genetic approach to understanding of the 
disease is on the rise. With development of phenotypic model of 
hypertension, namely the Spontaneous Hypertensive Rats (SHR) by 
Okamoto and Aoki in 1963 [40], the research to understand genetic 
predictors of disease and therapy has taken a fore step. 
 Experts opine that SHR models could be taken as counterpart for 
understanding clinical hypertension and its complications as well.[41] But 
with expansion of genetic tools , Genotypic models evolved to provide 
pin point focus on the genetic predictors of disease and disease 
progression. 
 
 
Milan Hypertensive strain (MHS) of rats were found do develop a 
form of hypertension with features of renal dysfunction analogous to 
changes seen in humans with Essential Hypertension. A point mutation in 
Animal models to 
understand genetic 
basis of Hypertension
Natural variants 
among inbred strains
Phenotypic models
eg: Spontaneous 
Hypertensive Rats
By genetic techniques
Genotypic models
eg: Transgenic animals
Fig.8: Genetic models for screening of antihypertensive activity in animals. 
 22
the genes coding for adducing protein in MHS rats was implicated for this 
feature by Bianchi et al. in 1994. The MHS rat strains differed from their 
normal counterparts by the amino acid sequence at 316th position by 
replacement of tyrosine instead of phenylalanine. [42] 
 After 2 years of deducing this finding, Tripodi et al. tried to 
discover the molecular mechanism of this mutated variant of Adducin 
gene in MHS rats. Several renal cell lines of rat and human origin were 
genetically engineered to produce transfected wildtype or mutated ADD-
1 genotypes. These modified genotypes showed increased expression and 
activity of Na+/K+ ATPase in the renal cells. Based on these observations, 
Torielli et. al postulated that mutated ADD-1 variants could be 
implicative in salt sensitive forms of Essential Hypertension.[43] 
 In 2004, further research on alpha Adducin by Efendiev et al. in 
MHS rats showed that the increased expression of Na+K+-ATPase  did 
not undergo downexpression or endocytosis in response to dopamine 
stimuli. Hence the researchers concluded that the dynamic regulation to 
natriuretic stimuli could be impaired in alpha adducin mutants.[44] 
              Results from various research endeavours in this field, threw light 
on key points about Alpha Adducin. Adducin is a ubiquitously present 
tetrameric cytoskeletal protein made up of an α and either a β/γ 
heterodimeric subunits. It is coded by 3 genes ADD-1(α), ADD-2(β) and 
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ADD-3(γ). It is involved in inter-cellular contact, signal transduction and 
cell membrane ionic transport. By means of positional cloning, α 
Adducin has been mapped at chromosome 4p16.3 
 
 
 Adducin is a term coined from Latin, ‘adducere’ meaning ‘to bring 
together’. This cytoskeletal protein was initially identified as a 
component in the spectrin-actin framework of erythrocytes.[45]Subsequent 
studies identified its major role in promoting the organisation of spectrin-
actin lattice formation. Adducin is a 200kD cytoskeletal protein 
belonging to the MARCKS- ‘myristoylated alanine rich C kinase 
substrate’ protein family.[46] It controls the rate of actin polymerization by 
capping the fast growing end of actin filaments. Its functioning is 
Fig.9: Mapping of Adducin loci in human genome. 
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dependent on calcium/calmodulin. It gets phosphorylated by Protein 
Kinase A/C, tyrosine and p-kinases. 
 
 
  
During the last decade of the 19th century, various researchers 
undertook genetic association studies to establish relationship of ADD-1 
polymorphism to Essential Hypertension. In a case-control study 
conducted by Casari et al. in 1995, 190 Essential Hypertension and 126 
Normotensive controls were screened for ADD-1 polymorphism linkage 
to Essential Hypertension. This study established a positive 
association.[47] 
Fig.10: Schematic representation to differentiate mechanism of  
wild ADD-1 (Gly460Gly) and mutant ADD-1(Gly460Trp)  
on renal tubular Na/K-ATPase. 
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 In 1997, genetic linkage of ADD-1 polymorphism, specifically 
Gly460Trp SNP variants were established to possess a strong linkage to 
salt sensitive forms of Essential Hypertension by Cusi et 
al.[48]Subsequently, research carried out by Manunta et al. on 108 
Essential Hypertension patients confirmed that ADD-1 mutants with SNP 
460Trp showed increased renal tubular sodium reabsorption.[49] 
 To further emphasise the relationship of Gly460Trp on renal 
tubular sodium reabsorption, Manunta et.al conducted endogeneous uric 
acid and lithium marker based studies to assess rate of renal tubular 
sodium reabsorption in Gly460Trp carriers. The results of their work 
established that Gly460Trp could be coined as ‘renal hypertensive gene’, 
since this variant was found strongly modulate renal sodium reabsorption 
and affect BP levels in Essential Hypertension subjects.[50] 
 The strength of relationship of Gly460Trp variant to Essential 
Hypertension was profound such that, the polymorphism was identified 
as an influential etiology for raised BP values in the genome-wide scan 
on cause of high BP values in familial combined hyperlipedemia among 
18 Dutch families conducted by Allayee et al.(2001)[51]  
 In order to identify whether single nucleotide mutation in  
ADD-1/ADD-2/ADD-3 was responsible for high BP, Low oubain and 
renin activity, Lanzani et al.(2005) screened 512 newly detected 
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treatment naïve Essential Hypertension patients. The results of this study 
also favoured Gly460Trp linkage to salt sensitive Essential 
Hypertension.[52] 
Translating this research finding into clinical utility the next 
escalatory approach of validation of Gly460Trp mediated salt sensitive 
Essential Hypertension. Hence researchers tried to investigate the 
responsiveness of Thiazide diuretics in Gly460Trp mutants. 
Cusi et al. performed an interventional study on 37 Gly460Gly and 
21Gly460Trp carriers of ADD-1 polymorphism, he treated these subjects 
with HCTZ 12.5mg for one month followed by 25mg dose the following 
month. The mean differences in MAP values between these two ADD-1 
genotypes were assessed at the end of study duration. Their study results 
showed that Gly460Trp mutants had 7.9mmHg extra fall in MAP values 
than their homozygous counterparts receiving the same intervention.[53]  
In the above study by Cusi et al., the genotype of the participants 
were already analysed prior to interventional drug administration. Hence 
subsequent research with the same intervention but post hoc genotyping 
was carried out by Glorioso et al. in 143 Caucasians (58 Italians, 85 
sardinians). The results of this study also elucidated an added 
antihypertensive clinical efficacy of Gly460Trp over Gly460Gly 
Essential Hypertension patients. In addition, the study also showed ethnic 
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variation in response to HCTZ treatment between Italian and Sardinian 
subjects.[54] 
Since ethnic variability in responsiveness of HCTZ existed within 
Caucasoid population themselves, many researchers independently took 
up this research question and tried to find answers among various 
countries and ethnicities. 
In a Meta-Analysis conducted by Liu et al. in 2010, from pooling 
data from 22 studies researching α-Adducin polymorphism to 
Hypertension risk, the positive correlation of Gly460Trp to Essential 
Hypertension risk was seen predominantly in Caucasian, European and 
East Asian subgroups of population and negative association in Afro-
American ethnicity.[55]  
On further scrutiny on these positively proven associations, lot of 
discrepancies were reported. Among Caucasoid ethnic groups, population 
of Australian [56] and Polish [57] origins were not found to have significant 
association. Similarly among Asian ethnic groups, Han & Mongolian 
Chinese [58], Japanese [59] and Koreans [60] did not show significant linkage 
of ADD-1 460Trp and Essential Hypertension risk. Till date the role of 
ADD-1 460Trp among various ethnicities is still under speculation. 
Focussing on Indian population and relationship of ADD-1 
genotype mutant on Essential Hypertension risk, the studies reported have 
been scarce. Ramu et al., conducted a case control study among 432 
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Essential hypertensive patients and 461 healthy controls from South 
Indian population. Their results were inconclusive with regards to 
establishing association between ADD-1 460Trp and Essential 
Hypertension susceptibility.[61] 
EXPERIMENTAL DRUGS USING ADDUCIN AS TARGET OF 
DRUG ACTION: 
In spite of all the inconclusive evidence relating to ADD-1 460Trp- 
Essential Hypertension-Thiazide responsiveness, Researchers have 
identified a novel compound –‘Rostafuroxin’, a compound capable of 
modulating Adducin based Na/K-ATPase activity in the renal tubules and 
regulating Endogenous Oubain (A genetically mediated salt regulating 
hormone in the body) levels. 
Rostafuroxin (PST2238) 
This compound is a digitoxigenin derivative capable of selectively 
displacing Oubain from its binding site without affecting the other 
hormonal targets or endocrinal milieu involved in blood pressure 
regulation.[62] 
In-vitro studies: Renal cells transfected with either ADD-1 
460Trpmutation or Oubain exposure, when subjected to Rostafuroxin 
showed decrease in Na/K-ATPase activity, since the drug could 
counteract both oubain binding and alpha adducin mediated molecular 
mechanisms.[63] 
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In-vivo animal studies:  
Milan Hypertensive strains of rats have been taken as the 
effective animal model in studying effects of Rostafuroxin. The reason 
for selection of this strain is due to the fact that these MHS rats express 
ADD-1 polymorphism and increased Oubain levels. Both these genetic 
determinants are associated with salt sensitive Essential Hypertension and 
cardiac hypertrophy in MHS rats.[64] 
MHS rats and Essential Hypertensive human subjects share many 
patho-physiological similarities with respect to Renal excretion of sodium 
after saline load, 24 hour urinary output, plasma renin, urine kallikrein as 
well.[65] 
Fig.11: Rostafuroxin effects on Oubain and Alpha Adducin mediated 
Hypertensive changes in preclinical studies. 
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Results of Preclinical toxicity studies done in rats and monkeys 
demonstrated the following parameters[66]: 
Acute toxicity following oral dose in rats LD50 >2000mg/Kg 
Chronic toxicity study (per os route) in rats NOAEL = 250µmol/Kg/day
Chronic toxicity study (per os route) in  
Monkey 
NOAEL = 450µmol/Kg/day
Genotoxicity Nil 
  
 
Fig.12: Molecular mechanism of action of Rostafuroxin 
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Rostafuroxin did not show inherent diuretic activity, hence the drug 
lacked diuretic-like adverse events such as alteration of uric 
acid/glucose/lipid metabolism, electrolyte abnormalities, counter-
regulatory changes mediated by RAAS, etc.[67] 
 
Clinical Trials with Rostafuroxin: 
 Rostafuroxin has successfully completed Phase I clinical trial in 
healthy volunteers.[67] Results from two exploratory Phase II studies done 
to establish efficacy and tolerability in mild Essential Hypertensive 
subjects was also successful and the effective dose was established as 0.1-
1mg/day per oral.[67]  
 A multicentric Phase II Trial on 440 uncomplicated, moderate 
Essential hypertensive participants from Europian countries was 
undertaken to explore the impact of genetic variations in Adducin 
genotypes (ADD-1, ADD-2 and ADD-3) and enzymes involved in 
Oubain homeostasis on BP titration with Rostafuroxin.[68]Hence a 
pharmacogenetic strategy to tackle Essential hypertension is under 
processing and the results are imminent. 
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PHARMACOGENOMIC APPROACH TO MANAGEMENT OF 
HYPERTENSION – A COST-EEFECTIVE ANALYSIS: 
 Though Thiazide based diuretic combination with other classes of 
antihypertensive agents have been highly recommended as first step 
treatment, 80% of hypertensives do not take diuretics.[69] Most often 
when patients are started on a drug regime, the decision to switch over to 
a better agent happens only when the physician decides to revise the 
existent prescription or patient reports back to a health care facility for 
follow-up/complaints/morbidity.  
 The reason for revision or escalation of a monotherapy to 
combination regimes could be due to ineffectiveness or adverse reaction 
of the first prescribed agent in that individual patient.  
 Hence a rationale prescription to treatment of Essential 
hypertension should take into consideration about various factors 
affecting drug action in each individual patient from the initial stage of 
pharmacological intervention. One such individualised approach is 
utilization of the person’s genomic profile and choosing a drug that 
would prove beneficial to the patient based on his/her genomic 
fingerprints. 
 Pre-prescription genotyping has been used as a tool for guiding use 
of some agents in routine practice. Examples are: CYP450 variants and 
VKORC1 variants in dosing serotonin reuptake inhibitors and warfarin 
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respectively.[70] Implementing a similar approach for guidance in 
prescription of medication for a complex polygenic disease like Essential 
hypertension in real time clinical setting could be quite daunting since 
Indian database of genomic evidence based medicinal practices are 
limited.[71] 
 Moreover for a complex polygenic disease, a single genotyping test 
alone would not provide a comprehensive list of all the genetic markers 
predicting drug action. But if that single gene plays a key role in dictating 
an individual’s response to the effective drug available for treatment of 
the disease, then such a pharmaco-genotyping screening test could be a 
revolutionary and pharmaco-economic option as well.[72] 
 Meckley & Veenstra conducted a study questioning the pharmaco-
economic outcome of using a pre-prescription screening test for 
Gly460Trp mutation among Essential Hypertensive for dictating usage of 
Thiazide diuretic over a conventional approach (no genotyping prior to 
drug administration). This study showed that patients who were screened 
for ADD-1 Gly460Trp mutation prior to Thiazide drug administration 
had an increased Quality Adjusted Life Years (QALYs) compared to their 
non screened counterparts. The genotypic screening saved $1834 
compared to the conventional care as well.[73] This study also served to 
establish the influential role exerted by ADD-1 Gly460Trp on Thiazide 
effectiveness as an antihypertensive agent. 
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 Hence an effective first step antihypertensive (Hydrochlorthiazide) 
with a determinant genetic target (ADD-1 Gly460Trp) translating to 
increased effectiveness of drug as well as pharmaco-economic benefit, 
with strong proof of evidence backed up by Rostafuroxin trials, with 
lacking evidence from Indian subset of population was a trigger to initiate 
our current study. 
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METHODOLOGY 
This study was conducted in the Hypertension Out-patient clinic of 
Government Kilpauk Medical College during the period of June, 2014 to 
June, 2015. Out of the total 165 essential hypertensive patients screened, 
100 subjects were included in the study, if the recruitment criteria were 
satisfied. 
Study Design: 
Allocation:  Stratified randomized  
Endpoint Classification: Safety/Efficacy Study 
Intervention Model:  Parallel Assignment 
Masking:   Open labelled 
Primary Purpose:   Treatment 
Condition : Essential hypertension 
Intervention : T. Hydrochlorthiazide (HCTZ) 12.5mg once 
daily dose in the morning after breakfast   
 
 The study was conducted after the approval from the Institutional 
Ethics Committee, GKMC. Patients attending Hypertension clinic, 
Government Kilpauk Medical College were briefed and explained about 
the process and need for this current study. Patient information sheet and 
consent form were given to the patients. Following consent to participate 
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in the study, patients were subjected to baseline investigations and 
screening for eligibility to become a participant in the further 
proceedings. 
Patients satisfying the following inclusion criteria were recruited in 
the study. 
Inclusion Criteria: 
1. Adult Essential Hypertensives (>18yrs, <70yrs) of either gender 
2. Patients with Essential Hypertension on regular pharmacotherapy 
and atleast 3 consecutive monthly BP records entered in their OPD 
treatment books.  
3. Essential hypertensives with associated co-morbidities: Renal 
dysfunction (Creatinine clearance > 60ml/min/sq.m), stable 
coronary artery disease, Old Cerebrovascular disease, controlled 
Diabetes mellitus 
Exclusion Criteria: 
1. Essential hypertensives (<18yrs, >70yrs), Pregnant women, 
Pregnancy related hypertensive disorders 
2. Patients with known Secondary hypertension. 
3. Essential hypertensive patients with poor glycemic control 
(HbA1c > 8.0%) 
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4. Patients with drug allergy to thiazide 
5. Essential hypertensives with hepatic dysfunction, alcoholics, 
chronic heavy smokers 
6. Hypertensives presenting with acute events or requiring In-
patient care 
 
Stratification factor :  
Average of 3 consecutive monthly BP recordings. If values  
> 140mmHg SBP or > 90 mmHg DBP, patient was allocated in 
Intervention arm. Other patients with controlled BP recordings were 
assigned to the Control arm. 
Baseline data collected on Day 1 and recorded in the case report form: 
 Demographic details 
 Anthropometry(BMI) 
 Duration and course of disease with management details 
from medical records 
 Blood Pressure readings from past 3 months 
 Lab investigations: CBC, RFT, LFT, FLP, RBS 
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All patients were followed up on a monthly basis. On each visit, their 
weight and right arm sitting posture BP were monitored. Patients were 
questioned about their general wellness levels and specific side effects at 
each visit. 4th follow up visit ( at the end of 3 months into study) included 
repeat of lab investigations.  
Fig.13: Participant Flow Diagram. 
*Analysis of all 50 participants allocated to the Interventional arm was  
carried out by the last observation brought forward method. 
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A 2ml blood sample for genotyping of α-Adducin polymorphism was 
carried out during the first follow-up visit, when patient reports back with 
the results from baseline investigations. The recruitment of the patient on 
the interventional drug (HCTZ) group was determined irrespective of the 
Adducin status. 
Sample collection:  
 Samples for baseline screening lab investigations were forwarded 
and processed by the Hospital Biochemistry wing. 2 ml of venous blood 
was collected under sterile aseptic precautions and transferred into EDTA 
tubes for genotyping procedures.  
Procedure for Genotyping alpha – Adducin polymorphism: 
Material & Methods: 
Consumables for Genotyping - DNA purification kit (PureFast® Human 
Blood Genomic DNA purification kit), PCR Master Mix,  Master Mix 
(2U of Taq DNA polymerase,  2mM MgCl2, 1μl of 10mM dNTPs mix, 
Taq reaction buffer and PCR additives), Agarose, TAE buffer, gel 
loading buffer and Ethidium bromide are from HELINI Biomolecules, 
Chennai. 
Tetra ARMS PCR primers were also designed and synthesised by 
HELINI Biomolecules, Chennai. 
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Principle: 
Cells are incubated for a short period with Proteinase K and chaotropic 
salts to inactivate all nucleases. Helini PureFast® kit utilizes an exclusive 
silica glass based membrane technology in the form of a convenient spin 
column, capable of recovering up to 20µg of DNA. Nucleic acids bound 
to this membrane is subjected to multiple “wash and spin” process for 
purification off cellular components. Final step uses low salt elution to 
release the nucleic acid from the glass fibre. 
 
 
 
 
 
 
Genomic DNA Purification from control & 
Test samples
PCR amplification using Tetra ARMS 
PCR primers
Agarose gel electrophoresis analysis of 
PCR amplified products
Genotyping by seeing each sample PCR 
band pattern
Fig.14: Overview of Genotyping procedure. 
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Procedure: Genomic DNA Extraction from venous blood sample 
1. 200µl of EDTA treated venous blood sample is taken in a fresh 
1.5ml centrifuge tube 
2. 400µl of Lysis Buffer is added to the blood and gentle vortex 
mixing is done 
3. To this mixture, 20µl of Proteinase K is added and vortex mixed 
for 10seconds 
4. Incubated for 15 mins in a 56ºC hot water bath 
5. Incubated sample is treated with 300µl of Isoproponal and entire 
sample is mixed well by inverting several times 
6. The entire sample is transferred into the PureFast® spin column 
and centrifuged at 12000rpm for 1 min. The flow-through is 
discarded thereafter. 
7. 500µl of 70% Ethanol is added into the spin column and 
centrifuged at 12000rpm for 1 min. Flow-Through is discarded 
8. Step 7 is repeated again 
9. Empty spin column centrifuge at 13000rpm for 2 mins is done to 
remove any residual alcohol from the sample 
10. The membrane is transferred into a fresh labelled 1.5ml micro 
centrifuge tube 
11. 60µl of pre-warmed Elution buffer is added to the centre of the 
membrane and incubated at room temperature for 2 mins 
12. Final centrifuge for 1 min at 12000rpm is done and the purified 
DNA collected in the micro centrifuge tube is stored at -20ºC for 
subsequent processes 
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PCR Amplification using Tetra ARMS primers: 
Primer for T 
allele: 
5’-CCGGGGCGACGAAGCTTCCGAGGGAT-3’ 
5’-
GATGTGGAGGTTCCTGCTAGTGTCACAGG- 
 
Primer for G 
allele: 
 
5’-GACTTGGGACTGCTTCCATTCTGTCC 
5’GGACGAGAGAGACTGCAGCAAGGGTTT 
 
PCR Product 
for T allele: 
120bp 
 
PCR product 
for G allele: 
180bp 
 
Two outer 
Primers: 
248bp 
 
 
Thermocycler PCR run was carried out with a  Reaction Volume of 25µl 
(PCR Master Mix- 10µl, Primer-10µl and 5µl of DNA sample) in the 
following temperature settings: Initial denaturation at 95ºC – 5min, 35 
cycles of (95ºC – 30sec, Annealing 60ºC – 30sec, 72ºC – 30sec) and final 
extension at 72ºC for 5 minutes. 
 
Gel Electrophoresis: 
2% agarose gel was prepared by mixing 0.6g of agarose powder with 
30ml of Tris-Acetate-EDTA buffer and heating in a microwave for 
1minute. 0.25µl of Ethidium bromide dye was mixed to this liquefied 
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agarose and poured onto the gel plate fixed with well cutter comb. After 
the gel sets, amplified PCR product was cast onto it. DNA ladder, 
Negative control and 6 PCR products could be loaded per electophoretic 
gel. Electrophoresis was carried out in a submarine type electrophoretic 
well apparatus at 100V for approximately 45 minutes. The gel film was 
then dismounted and used for band visualization immediately.  
Visualization of DNA Bands: 
The gel film is visualised under UV filter and camera capture of each run 
was saved in the computer software. Using the DNA ladder as a guide, 
DNA bands of Outer Primers (248bp), PCR product of T allele (120bp) 
and G allele (180bp) could be identified. 
 
 
 
Fig.15: An example to explain interpretation of ARMS PCR gel 
electrophoresis film. 
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Statistical Analysis: 
 All patient particulars were charted onto Microsoft 2007 Excel 
sheet systematically. Descriptive statistics was applied to describe 
demographic and laboratory investigations. Microsoft Excel generated 
graphical representations of data were also included to express results. 
SPSS software version 13.0 was used. Inferential statistics was applied to 
assess difference in means between and within groups of allocation and 
genotypes (ANOVA, t test). Chi square test was used to determine 
statistical significance and establishing association between each subset 
projected onto the entire group. Levene's Test for Equality of Variances 
to assess impact of HCTZ among Genotypically classified Control and 
Test arms was also assessed.    
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RESULTS 
1. Demographic characteristics of Study Population: 
 
 Age of study participants ranged from 36 to 64 years. The mean age of 
study participants was 52.16years (Average age of Control and Test arm 
participants was 51.58yrs and 52.74yrs respectively.) 
 The study participants fell under three ADD-1 Genotype categories 
when ARMS-PCR assay was carried out. The Genotype categories were: 
Gly/Gly, Gly/Trp, Negative. The primary study objective was to assess 
the relationship of Gly/Trp to Essential Hypertension and 
Hydrochlorthiazide responsiveness. 
 Genotype based distribution of ADD-1 gene among the 100 
Essential Hypertension patients allocated to Test and Control arms is 
represented by the graph that follows:  
< 40 40-45 45-50 50-55 55-60 60-65
Control Arm (n) 1 6 11 15 11 6
Test Arm  (n) 2 4 4 16 18 6
0
2
4
6
8
10
12
14
16
18
20
Age profile of Participants
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Age wise Genotype distribution among recruited subjects:   
  Genotype Total P value
  Gly/Gly Gly/Trp Negative   
Age 
in 
years 
18-40 Count 2 1 2 5 0.489
  % within Age in years 40.0% 20.0% 40.0% 100.0%  
  % within Genotype 3.9% 7.7% 5.6% 5.0%  
 41-50 Count 20 2 8 30  
  % within Age in years 66.7% 6.7% 26.7% 100.0%  
  % within Genotype 39.2% 15.4% 22.2% 30.0%  
 51-60 Count 27 10 24 61  
  % within Age in years 44.3% 16.4% 39.3% 100.0%  
  % within Genotype 52.9% 76.9% 66.7% 61.0%  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Control Test
Negative 25 11
Gly/Trp 1 12
Gly/Gly 24 27
Genotype distribution among Patients
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 Above 60 Count 2 0 2 4  
  % within Age in years 50.0% .0% 50.0% 100.0%  
  % within Genotype 3.9% .0% 5.6% 4.0%  
Total Count 51 13 36 100  
 % within Age in years 51.0% 13.0% 36.0% 100.0%  
 % within Genotype 
100.0
% 100.0% 100.0% 100.0%  
Gender wise Genotype distribution among patients: 
 
 
     
Genotype Total 
Chi 
square 
P value 
    Gly/Gly Gly/Trp Negative    
Gender Male Count 23 9 18 50 .299
    % within 
Gender 
46.0% 18.0% 36.0% 100.0
% 
    % within 
Genotype
45.1% 69.2% 50.0% 50.0% 
  Female Count 28 4 18 50 
    % within 
Gender 
56.0% 8.0% 36.0% 100.0
% 
    % within 
Genotype
54.9% 30.8% 50.0% 50.0% 
Total Count 51 13 36 100 
  % within 
Gender 
51.0% 13.0% 36.0% 100.0
% 
  % within 
Genotype
100.0% 100.0
%
100.0% 100.0
% 
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 Age and gender based distribution of α-Adducin genotype among 
the participants did not show any statistical significance as seen in the 
crosstables above. 
2. Hypertension profile of study participants: 
 As per the study protocol, Patients were recruited into Test and 
Control arms based on the SBP/DBP cut-offs. Average three monthly 
records that were consistently > 140/90mmHg (in spite of 
pharmacotherapy) was taken as the stratification set point. Hence among 
Control arm, all the participants fell in Normal or Prehypertension grade 
(with pharmacotherapy) of JNC- 8 grade of hypertension. Similarly, Test 
participants fell under Stages I & II only. 
Stage of Hypertension among Control and Test Participants 
 
Test
Control
0
5 45
19
0
31
Staging of Hypertension among Patients
Normal Prehypertension Stage I Stage II
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 In the Control arm, 5 patients had Normal BP and 45 patients fell 
in the Pre-Hypertension stage. The Test arm included 19 patients in Stage 
I and 31 patients in Stage II Hypertension respectively. 
Genotype of participants with regards to their baseline grading of 
Hypertension: 
 
   Genotype Total P value
    Gly/Gly Gly/Trp Negative    
 
 
 
 
 
.018* 
Staging 
(Baseline) 
Normal Count 3 0 2 5 
    % within 
Staging  
60.0% .0% 40.0% 100.0% 
    % within 
Genotype 
5.9% .0% 5.6% 5.0% 
  Pre HT Count 21 2 24 47  
    % within 44.7% 4.3% 51.1% 100.0% 
0
5
10
15
20
25
30
Gly/Gly Gly/Trp Negative Gly/Gly Gly/Trp Negative
Control Test
Stage II
Stage I
Prehypertension
Normal
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Staging  
    % within 
Genotype 
41.2% 15.4% 66.7% 47.0% 
  Stage 1 Count 16 8 8 32 
    % within 
Staging  
50.0% 25.0% 25.0% 100.0% 
    % within 
Genotype 
31.4% 61.5% 22.2% 32.0% 
  Stage 2 Count 11 3 2 16 
    % within 
Staging  
68.8% 18.8% 12.5% 100.0% 
    % within 
Genotype 
21.6% 23.1% 5.6% 16.0% 
Total Count 51 13 36 100 
  % within 
Staging  
51.0% 13.0% 36.0% 100.0% 
  % within 
Genotype 
100.0% 100.0% 100.0% 100.0% 
 
 Among the 100 study participants, 51% had Gly460Gly and 13% 
had Gly460Trrp genotype of α-Adducin. 36% of patients were negative 
for either of the genotypic traits. Baseline staging wise genotype 
distribution showed a statistical significance   (p-0.018) 
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Descriptives of Baseline Mean Arterial Pressure based on Genotype: 
 
N Mean Std. Deviation 95% Confidence Interval for Mean 
Min 
value 
Max 
value P value 
        
Lower Bound Upper Bound 
    
0.012 
Gly/Gly 51 105.2941 11.17092 102.1522 108.4360 83.33 126.67
Gly/Trp 13 109.5385 6.84422 105.4025 113.6744 96.67 120.00
Negative 36 100.3889 9.66010 97.1204 103.6574 83.33 120.00
Total 100 104.0800 10.55084 101.9865 106.1735 83.33 126.67
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Mean Arterial Pressure (Calculated) values, when sorted according to the 
genotypes, also showed statistically significant intergroup differences 
when Chi-square test was applied. 
3. Baseline Antihypertensive agents used among Control and Test 
arm  
Three classes of pharmacological intervention were being used in our 
site.  
Namely : 
o ACE inhibitor – T. Enalapril 2.5mg 
o Calcium Channel Blocker-T.Amlodipine 2.5mg  
o Cardioselective Beta Blocker – T. Atenolol 50mg 
 Among the Control Arm, the most common antihypertensive used 
was Enalapril monotherapy (especially in Prehypertension stage), other 
participants most often had a combination of Amlodipine plus various 
other classes of antihypertensives available. 
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 The Test arm participants were most often treated with Enalapril 
based combination with either Amlodipine/Atenolol or all three agents 
together. In spite of using all the three classes of antihypertensive agents 
in our setup, their average consecutive three monthly BP values remained 
above 140/90mmHg. 
 In our study, patients with a consecutive three monthly average BP 
over 140/90mmHg in spite of using 2 or 3 different classes of 
pharmacological agents (though none of the drug regimen included a 
diuretic) were recruited in the Test arm and received T.HCTZ 12.5mg 
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once in the morning dose for 3 months along with their baseline 
antihypertensives. 
4. Co-morbid Illness profile 
 Co-morbid illnesses seen among recruited EH patients were: 
Diabetes Mellitus- Type II, Coronary Artery Disease, 
Hypothyroidism. 
 Medical records of management of Co-morbid illnesses were 
traced and relevant treatment history was also taken into account.  
 
As per the study protocol, patients with documented Chronic 
Liver/Kidney diseases were not included in study. 
5. Concomitant Medication usage among Participants 
50% of participants in the Control arm and 56% of participants in the 
Test arm did not receive any other concomitant medicaments. The rest of 
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the study participants were receiving treatment for their Diabetes and 
Coronary Artery Disease. Both the Test and Control arm had one EH 
patient with hypothyroidism on Thyroxine supplementation. 
 
 
Nil
48%
Metformin
12%
Metformin+Sulfon
ylurea
19%
Insulin
2%
Atorvastatin
12%
Aspirin
5%
Thyroxine
2%
CONCOMITANT MEDICATION AMONG TEST ARM 
Nil
48%
Metformin
2%
Metformin+Sulfon
ylurea
23%
Insulin
0%
Atorvastatin
25%
Aspirin
0%
Thyroxine
2%
CONCOMITANT MEDICATION AMONG CONTROL 
ARM 
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6. Laboratory parameter profile of Participants 
 
 The above table shows the Range, Average, Maximum and 
Minimum values of all the baseline screening laboratory investigations 
taken from all the 100 subjects. 
7. Hydrochlorthiazide intervention versus Genotype distribution 
   Genotype Total Chi square p value 
    Gly/Gly Gly/Trp Negative    
HCTZ No Count 24 1 25 50 .001
    % within HCTZ 48.0% 2.0% 50.0% 100.0% 
    % within 
Genotype 
47.1% 7.7% 69.4% 50.0% 
  Yes Count 27 12 11 50 
    % within HCTZ 54.0% 24.0% 22.0% 100.0% 
    % within 
Genotype 
52.9% 92.3% 30.6% 50.0% 
Total Count 51 13 36 100 
  % within HCTZ 51.0% 13.0% 36.0% 100.0% 
  % within 
Genotype 
100.0% 100.0% 100.0% 100.0% 
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On Statistical evaluation to assess relationship between 
Hydrochlorthiazide administration and genotype profile(Gly460Gly/ 
Gly460Trp / Negative) among test and control arm, the results were 
highly significant.  
8. Follow-up vs Baseline Blood Pressure changes among test and control 
arm 
Decrement in 
BP(Follow-up minus 
Baseline values) 
Allocation N Mean Std. 
Deviation 
Std. Error 
Mean 
SBP - Difference Control 50 -1.3600 3.66873 .51884 
Test 50 -9.2000 7.22806 1.02220 
DBP - Difference Control 50 -1.8800 4.50687 .63737 
Test 50 -6.6800 4.47414 .63274 
MAP - Difference Control 50 -1.7067 3.61443 .51116 
Test 50 -7.5200 4.24219 .59994 
  
Mean Arterial Pressure is a calculated parameter.  
[MAP = DBP+1/3(SBP-DBP)] 
Hence a MAP value above 106.67mmHg could be considered as 
allocation into Test arm of study. A schematic representation of the 
change in MAP values after three months of conventional 
pharmacotherapy (among control subjects) and additional HCTZ therapy 
(among test subjects) is as follows: 
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 Patients who received Hydrochlorthiazide 12.5mg as an addition to 
their existent antihypertensive agents, invariably had a reduction in their 
SBP, DBP and calculated MAP values from their corresponding baseline 
recordings. 
9. Genotype influence on BP changes among Test and Control 
 When all 100 participants were assessed based on their genotype 
status to assess for intergroup variation in changes in MAP values, 
statistical significance was established. (Chi-square test) 
 N Mean Std. 
Deviation
95% Confidence 
Interval for Mean
Min 
value 
Max 
value 
P 
value
        Lower 
Bound 
Upper 
Bound 
    0.019
Gly/Gly 51 101.93 5.712 100.33 103.54 93 113 
Gly/Trp 13 103.49 4.862 100.55 106.43 97 110 
Negative 36 99.26 4.825 97.63 100.89 93 110 
Total 100 101.17 5.469 100.09 102.26 93 113 
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Subsequently, Levene's Test for Equality of Variances to assess impact of 
HCTZ among Genotypically classified Control and Test arms was 
applied. The following results showed highly significant statistical P 
values. 
    F Sig. t df 
Sig. (2-
tailed) 
SBP - 
Difference 
Equal 
variances 
assumed 
22.134 .000 -9.212 98 .000
  Equal 
variances not 
assumed 
  -9.212 72.676 
DBP - 
Difference 
Equal 
variances 
assumed 
.629 .430 -9.531 98 .000
  Equal 
variances not 
assumed 
  -9.531 97.995 
MAP - 
Difference 
Equal 
variances 
assumed 
1.872 .174 -11.706 98 .000
  Equal 
variances not 
assumed 
  -11.706 95.590 
 
The results of ANOVA parametric test to establish statistical significance 
to test the difference in means of SBP, DBP and MAP values and the 
influence of ADD-1 Genotypes (Gly460Gly ,Gly460Trp and Negative) 
on BP reduction among the Test arm of patients are follows: 
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    Sum of 
Squares df
Mean 
Square F Sig.
SBP - 
Difference 
Between 
Groups 
475.652 2 237.826 4.170 .018
  Within 
Groups 
5531.708 97 57.028    
  Total 6007.360 99      
DBP - 
Difference 
Between 
Groups 
209.151 2 104.575 2.819 .065
  Within 
Groups 
3598.849 97 37.102    
  Total 3808.000 99      
MAP - 
Difference 
Between 
Groups 
252.692 2 126.346 3.607 .031
  Within 
Groups 
3397.548 97 35.026    
  Total 3650.240 99      
 
 When individual genotype influence on HCTZ responsiveness in 
the 50 test population was assessed, Gly460Gly and Negative carriers had 
significant results. Gly460Gly homozygous genotype was seen in 
27(54%) test participants.   
 The mean reduction in their SBP, DBP and MAP values following 
HCTZ add on for 3 months are as follows: 11.41, 6.07, 7.85 mmHg 
respectively. 11(22%) test subjects were negative for ADD-1 
polymorphism, their mean decline in BP parameters after HCTZ use was 
SBP by 6.18, DBP by 8.55 and MAP by 7.76mmHg. These BP 
decrements were also significant with respect to genotype variation in BP 
reduction with HCTZ usage. 
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 Since Analysis of Variance results were significantly different 
among the three genotypic groups, individually each genotype based 
comparison was done to assess their influence on decrements in BP 
values among Test and Control arms were assessed. 
 Genotype Gly/Gly  
 
  
Allocation 
Control Test 
Mean SD Mean SD 
SBP - 
Difference -1.58 4.13 -11.41 6.32 
DBP - 
Difference -1.75 4.22 -6.07 4.35 
MAP - 
Difference -1.69 3.26 -7.85 4.37 
 
Levene's Test for Equality of Variances 
  
    F Sig. T df 
Sig. (2-
tailed) 
      
SBP - 
Difference
Equal variances 
assumed 4.116 .048 -8.571 49 <.001
  Equal variances 
not assumed   -8.780 45.179 
DBP - 
Difference
Equal variances 
assumed 1.095 .300 -6.499 49 <.001
  Equal variances 
not assumed   -6.510 48.596 
MAP - 
Difference
Equal variances 
assumed 5.480 .023 -8.752 49 <.001
  Equal variances 
not assumed   -8.903 47.642 
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 Among the Gly460Gly participants, between the Test and Control 
arms, statistical high significance was established as an impact of using 
HCTZ in test subjects.  
 Genotype Gly/Trp  
 
  
Allocation
Control Test 
Mean SD Mean SD
SBP - 
Difference .00 . 7.00 7.56
DBP - 
Difference .00 . 6.33 5.84
MAP - 
Difference .00 . 6.56 5.00
 
 
Since there was only one Gly460Trp participant in the control arm and 12 
in the Test arm, Comparability and applicability of inferential statistical 
tests were obsolete. 
 Genotype Negative 
  
  Allocation Levene’s Test 
  Control Test For equality of 
variance 
  Mean SD Mean SD Sig. (2-tailed) p 
value 
SBP - Difference -1.20 3.32 -6.18 7.77 <.001
DBP - Difference -2.08 4.92 -8.55 2.54 <.001
MAP - 
Difference 
-1.79 4.04 -7.76 3.09 <.001
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Between the test and control participants with neither ADD-1genotypic 
variants, statistically high significant decrement in BP was seen as a 
result of adding adjuvant HCTZ to the test arm. This result was similar to 
Gly/Gly Variant. 
10. Influence of Gly/Trp on BP changes vs other Genotypes (Gly/Gly 
and Negative) in Test arm 
ANOVA was applied to assess inter-genotypic variation in delta MAP 
values (Follow-up minus Baseline MAP) in the 50 patients allotted in 
Test arm alone. 
Groups Count Sum Average Variance P value 
Gly/Gly 27 -212 -7.85185 19.08832 0.672622 
Gly/Trp 12 -78.6667 -6.55556 25.03704  
Negative 11 -85.3333 -7.75758 9.535354  
 
On individually comparing Gly/Trp group vs Gly/Gly and Negative 
genotypes, the following results were obtained. 
Gly/Trp vs Negative 
Groups Count Sum Average Variance P-value
Gly/Trp 12 -78.6667 -6.55556 25.03704 0.500634
Negative 11 -85.3333 -7.75758 9.535354   
 
Gly/Trp vs Gly/Gly 
Groups Count Sum Average Variance P-value 
Gly/Trp 12 -78.6667 -6.55556 25.03704 0.418523
Gly/Gly 27 -212 -7.85185 19.08832   
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Though there was a statistically high significant inter-genotypic 
difference with regards to BP changes between Control and Test arm 
subjects, when ANOVA was applied to assess the same question in Test 
arm subjects alone, results were not statistically significant. Meaning, that 
Gly460Trp carriers did not show superior HCTZ antihypertensive 
response than Gly40Gly or Negative genotype carriers. Since ANOVA 
parametric test to assess difference in mean of MAP changes between the 
genotype classes did not produce significant results, t test was not 
required further. 
11. Safety check on HCTZ use among test subjects. 
Parameter Control Test 
Follow-up Hemoglobin (g/dl) 12.18+1.11 12.17+1.12 
Follow-up Platelets (cells/cu.mm) 235886+50098.38 235589.58+50105.15
Follow-up Total Protein (g/dl) 6.90+0.39 6.90+0.39 
Follow-up Total Bilirubin (mg/dl) 0.81+0.08 0.81+0.08 
Follow-up SGOT (U/L) 29.63+6.17 29.53+6.23 
Follow-up SGPT (U/L) 26.07+8.41 26.16+8.53 
Follow-up SAP (IU/L) 66.37+14.19 66.53+14.29 
Follow-up Urea(mg/dl) 27.26+4.55 27.44+4.53 
Follow-up Creatinine (mg/dl) 0.837+0.13 0.84+0.14 
Follow-up Sodium (mEq/L) 137.48+3.83 137.49+3.86 
Follow-up Potassium (mEq/L) 3.80+0.32 3.79+0.33 
Follow-up Random Blood Sugar (mg/dl) 147.45+48.24 149.47+48.11 
Follow-up Total Cholesterol (mg/dl) 172.73+39.07 172.36+39.67 
Follow-up Triglycerides (mg/dl) 156.40+61.17 157.11+61.91 
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Hydrochlorthiazide 12.5mg once daily dosage, as an add- on agent 
in management of Essential hypertension in the 50 Test participants did 
not produce significant adverse events. The follow-up laboratory 
parameters did not show significant variation from the counterpart 
recordings among the Control arm participants.  
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DISCUSSION 
 
This current study was conducted among 100 Essential 
Hypertension patients to find the prevalence of ߙ-Adducin mutation 
(Gly460Trp) and assess association of this genotypic variant on Blood 
Pressure control obtained by Hydrochlorthiazide add-on therapy among 
South Indian population. 
 Equal gender distribution was made possible by means of effective 
block randomization techniques used during recruitment of study 
participants. The mean age of study participants was 52.16years, with 
male and female gender wise age averages being 52.48 and 51.84 years 
respectively. Hence age and gender based variability of study parameters 
were not necessitated in the subsequent analysis.  
 The genotype distribution among study participants fell under three 
categories: Gly460Gly, Gly460Trp and Negative. The percentage 
distribution of these genotypes among the 100 EH patients was 
Gly460Gly (51%), Gly460Trp (13%), Negative (36%). In a cross 
sectional study conducted among 432 South Indian population to assess 
prevalence of ADD-1 polymorphism by Ramu et al., the genotypic 
distribution was Gly460Gly- 59.1%, Gly460Trp-35.6%, Trp460Trp- 
5.3%.[74] In our study, we did not encounter Trp460Trp variant and the 
frequency of Gly460Trp mutant was also comparatively low. 
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 On analysing Ethnicity based prevalence of Gly460Trp among 
Asians, Caucasians and Blacks, the frequency distribution noted was 
55.7%, 20.9% and 6.5% respectively.[75]  Hence it could be accepted that 
Ethnic inheritance of Gly460Trp is varied and could aid in the etio-
pathogenesis of Essential Hypertension. 
  Among our study population, the Gly460Trp genotype was 
distributed predominantly in the test arm subjects (BP>140/90mmHg). 
The percentage prevalence of this SNP according to JNC8 classification 
of Hypertension was 61.5% in Stage I, 23.1% in Stage II and 15.4% in 
Pre-hypertension grade. Hence it could be possible that the higher 
grading of Hypertension among these patients was probably due to 
increased renal tubular reabsorption of sodium mediated by Gly460Trp.  
 Though the staging of Hypertension noted among Gly460Trp 
genotype carriers in our study group was higher, the mean duration of 
hypertension noted among the three genotypes among test participants 
was not grossly different. Gly460Trp carriers in our study did not have 
complications of hypertension like Coronary Artery Disease/ Renal 
Dysfunction or Cerebro-Vascular Accidents. 
 In a prospective observational study conducted by Gerhard et.al on 
the participants of INVEST Trial, Hypertensive Black patients with 
Gly460Trp mutation showed a 2.6-fold additional risk of hypertension 
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related cardiovascular complications, but White and Hispanic ethnic 
counterparts did not show such excess risk.[76] A case-control study 
conducted among 560 men who survived Myocardial Infarction and 646 
men who underwent orthopaedic surgery in Netherland by Psaty BM et 
al., ADD-1 460Trp was not found to be linked to cardiovascular event 
risk in Hypertensive patients.[77]Our  study also projects that Gly460Trp 
has no additional cardiovascular morbidity associated to it. 
 All the study participants recruited in the study were 
Hydrochlorthiazide naïve. On analysing their baseline antihypertensive 
regimen, it was interesting to note that, compared to the other two 
genotype counterparts (Gly460Gly & Negative), Gly460Trp carriers 
required more than one drug for management of their BPs irrespective of 
whichever arm they were allocated. Enalapril based combination with 
Amlodipine was used in 12 out of 13 Gly460Trp mutants. 
 92.3% of Gly460Trp carriers fell in the Test arm and received the 
intervention. This genotype based association of Gly460Trp into 
Interventional arm was statistically significant in our study. 
 Irrespective of the genotype, HCTZ add on therapy produced 
significant reduction in BP values in the test participants compared to the 
control group. In other words, HCTZ produced an additional 8mmHg 
decrease in SBP, 5mmHg decline in DBP and 6mmHg decrement in 
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MAP of test subjects compared to control subjects in our study. This 
decrement is in concurrence with the results of Meta-Analysis conducted 
by Messereli et al. with data from 14 RCTs comparing HCTZ 12.5mg 
dose based combination therapy efficacies.[78] 
 Genotype based Blood pressure changes with HCTZ usage among 
our study participants was found to have statistically significant inter-
genotypic variation especially with regards to decrease in SBP and MAP 
values. In a ADD-1 genotype linkage study to establish HCTZ 
responsiveness in salt sensitive EH by Cusi & Bianchi et al., significant 
genotype based difference in BP titrations were seen.[79] This finding is 
consistent to our study results as well.  
 In the same study mentioned above by Cusi & Bianchi et al., they 
noted significant decline in MAP values among Gly460Trp carriers 
(14.7mmHg) following 2 months treatment with HCTZ than the 
homozygous Gly460Gly (6.8mmHg) counterparts.[79] Though in our 
study, Gly460Gly carriers responded in a comparable manner (delta MAP 
= 7.85mmHg) to their research participants, the superior response of 
Gly460Trp stated by their study could not be found among our study 
subjects.  
 In fact, when we tried to assess the difference in mean BP 
reductions between Gly460Gly and Gly460Trp Test arm participants 
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alone, the results were not statistically significant. Hence as per results of 
our study, Gly460Trp carriers did not have an added efficacy of HCTZ 
12.5mg/day over Gly460Gly carriers was used as an add-on anti-
hypertensive for 3 months. 
 Another notable finding in our study was the low frequency of 
distribution of Gly460Trp SNPs among our study population. Out of the 
13 carriers of this mutation, 12 participants fell in the Test arm and one 
patient was identified among the Control arm. Hence we were unable to 
apply comparisons and inferential statistical tools to study impact of this 
genotype between test and control arms.  
 According to a community based sampling of 585 adults  
(Afro-American and Non-Hispanic White ethnic origin) on 4 weeks of 
HCTZ therapy, a nested case-control study based on the DBP tertiles was 
done by van-der Zee et al., they tried to uncover the influential 
pharmacogenetics guiding HCTZ responsiveness.[80]In their study, the 
frequency of Gly460Trp was found to be 0.13% and this SNP was 
allotted as rare allele frequency determinant of HCTZ responsiveness. 
Based on this observation, the Gly460Trp could have been a rare genetic 
mutation of ADD-1 among our study population as well. 
 Despite promising evidence supporting ADD-1 Gly460Trp 
mutation in Essential Hypertension and its regulatory impact on Thiazide 
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responsiveness from western literature, our study conducted among 100 
patients of South Indian origins had low prevalence of this genetic variant 
hence making substantial correlation between ADD-1 Gly460Trp versus 
Hydrochlorthiazide efficacy difficult to establish.  
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CONCLUSION 
Based on our study findings we conclude that,  
 Three genotype classes were identified in our population: Gly460Gly 
(Homozygous), Gly460Trp (Heterozygous) and Negative (neither 
Homozygous nor Heterozygous). 
 The prevalence of ADD-1 Gly460Trp mutation in our subset of 
population is low. 
 Though the prevalence of Gly460Trp carriers were low it was 
significantly associated with higher staging of Essential 
Hypertension in spite of more than one class of pharmaco-
therapeutic intervention as per our study results. 
 Though higher staging classification was noted among Gly460Trp 
carriers of EH, propensity towards progression to CAD/CVA/CKD 
was not seen in our population. 
 Irrespective of genotypic variations in ADD-1, Hydrochlorthiazide 
12.5mg once/day addition to the other class of antihypertensive 
agents produced additive antihypertensive efficacy of the regimes 
used. 
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 The low frequency of Gly460Trp distribution among Control Arm in 
our study did not give room for application of Inferential statistics. 
 Gly460Trp was a low frequency genotype trait and did not show 
statistically different endpoint result variations in comparison to the 
other 2 genotypes (Gly460Gly & Negative) in our study 
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LIMITATIONS OF THE STUDY 
 Our study results are based on a sample size of 100 Essential 
Hypertension patients, out of which only 50 participants with consistent 3 
monthly BP values >140/90mmHg were given HCTZ 12.5mg as 
intervention for 3 months.  
  We designed the protocol with this BP cut-off as the stratification 
set point of allocation to have an unbiased approach to reveal the 
pharmacogenetic influence of ADD-1 on HCTZ action. The low 
frequency of Gly460Trp genotype and lack of significant association of 
this genotype to HCTZ efficacy could be attributed to low sample size. 
 ARMS-PCR (using customized primers) with gel electrophoresis 
and UV filter visualization of DNA bands though a sensitive method in 
detecting ADD-1 genotype variants is a qualitative method only. Further 
quantification of the genotype was not carried out in our study. 
 Other pharmacogentic influencers of HCTZ action were also not 
explored in our study. Hence the negative genotype carriers of ADD-1 
polymorphism could have had other possible genetic predictors of HCTZ 
action. 
 Data regarding influence of dietary habits, alcohol intake, smoking 
history were not included in our study. 
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SCOPE FOR FUTURE STUDY 
 Large sample size studies to establish association of ADD-1 
polymorphism on Essential Hypertension and Antihypertensive 
agent responsiveness in our Ethnic group of population and 
establishment of Indian guidelines for management of EH  
 Identification of genetic predictors of drug responsiveness could 
pave way in designing a personalized approach in EH management 
and translation into clinical practice 
  If a genetic marker with significant linkage and profound impact 
on any of the existent antihypertensive drug class responsiveness 
gets uncovered in our population, it could decrease the demand on 
the Antihypertensive drug pipeline and also be a pharmaco-
economic option from the health care system and patient 
perspective. 
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1 38 F 23.4 2 136 84 101.3 C Gly/Gly 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 140 80 100 
2 49 M 24.8 1 130 80 96.7 C Gly/Gly 0 2 0 0 0 0 0 0 0 0 3 2 0 0 1 0 0 130 84 99.3 
3 55 F 26.4 9 130 90 103.3 T Gly/Trp 2 0 0 1 
1
0 
0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
4 62 F 23.4 10 130 70 90 C Gly/Gly 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
5 55 F 28.6 10 160 100 120 T Gly/Gly 0 4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
6 41 F 26.8 1 130 90 103.3 T - 0 1 0 1 0 0 0 0 0 0 2 1 0 0 0 0 0 130 80 96.7 
7 45 F 23.2 10 150 90 110 T Gly/Gly 2 0 0 1 4 0 0 0 0 0 2 0.5 0 0 0 0 0 140 86 104 
8 37 F 24 2 150 96 114 T Gly/Gly 1 0 0 1 2 0 0 0 0 0 0 0 1 0 0 0 1 138 90 106 
9 48 F 26.4 9 160 96 117.3 T Gly/Trp 0 2 1 1 0 0 0 0 0 10 0 0 0 0 0 0 0 140 80 100 
10 44 F 23.8 4 160 100 120 T Gly/Gly 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 144 90 108 
11 56 F 27.4 3 110 70 83.3 C - 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 120 80 93.3 
12 52 F 26.2 7 130 80 96.7 C Gly/Gly 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 130 80 96.7 
13 45 F 25.8 1 130 80 96.7 C Gly/Gly 0 2 1 0 0 0 0 0 0 8 0 0 0 0 0 0 0 130 86 100.7 
14 57 F 23.4 6 160 100 120 T Gly/Gly 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 92 108 
15 58 M 22.6 8 160 100 120 T Gly/Gly 4 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 140 90 106.7 
16 54 F 26.4 10 150 96 114 T - 
 
0 1 1 6 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
17 36 M 23.8 5 140 100 113.3 T Gly/Trp 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 130 90 103.3 
18 47 M 24.8 7 130 80 96.7 C Gly/Gly 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
19 60 M 23.4 12 166 100 122 T Gly/Gly 2 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 148 90 109.3 
20 60 M 25 12 150 100 116.7 T - 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 138 88 104.7 
21 64 F 27.2 10 130 80 96.7 C Gly/Gly 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
22 50 F 24.4 9 140 100 113.3 T Gly/Gly 0 4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 128 90 102.7 
23 60 F 23.6 10 130 86 100.7 C - 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
24 58 F 25.8 9 140 90 106.7 T - 2 2 0 1 0 0 0 0 0 0 2 0 2 0 0 0 0 140 84 102.7 
25 40 F 22.6 2 130 80 96.7 C - 2 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
26 52 F 21.8 12 130 80 96.7 C Gly/Gly 2 2 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 130 80 96.7 
27 59 F 22.5 6 140 90 106.7 T Gly/Gly 2 2 0 1 2 0 0 0 0 0 3 2 0 0 0 0 0 130 90 103.3 
28 58 F 22.8 2 180 100 126.7 T Gly/Gly 2 4 0 1 8 0 0 0 0 0 3 0 0 30 0 0 0 160 90 113.3 
29 48 F 23.2 7 130 80 96.7 C Gly/Gly 4 4 0 0 3 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
30 45 F 23.4 3 110 70 83.3 C - 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 120 80 93.3 
31 49 F 22.8 3 120 80 93.3 C Gly/Gly 2 2 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 120 80 93.3 
32 52 F 24.6 6 160 80 106.7 T Gly/Trp 4 4 0 1 2 0 0 0 0 0 2 0 2 0 0 0 0 140 80 100 
33 55 F 25.8 8 150 90 110 T Gly/Gly 4 0 0 1 
1
5 
0 0 0 0 0 2 0 0 0 0 0 0 140 90 106.7 
34 45 F 23.5 1 130 70 90 C Gly/Gly 2 4 1 0 1 0 0 0 0 0 2 0 2 0 0 0 0 130 80 96.7 
35 50 F 21.4 5 150 100 116.7 T Gly/Gly 2 2 0 1 2 0 0 0 0 0 2 0 0 0 0 0 0 140 90 106.7 
36 52 F 22 7 140 100 113.3 T - 0 2 1 1 2 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
37 50 F 23.2 1 110 80 90 C Gly/Gly 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 120 80 93.3 
38 50 F 26.4 8 150 100 116.7 T - 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
39 54 F 21 2 140 100 113.3 T Gly/Trp 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
40 53 F 22.4 5 130 80 96.7 C - 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
41 53 F 19.8 5 130 70 90 C - 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
42 61 F 24 5 160 90 113.3 T - 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 146 86 106 
43 58 F 23.6 10 130 80 96.7 C - 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
44 63 M 20.4 8 130 86 100.7 C - 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 90 103.3 
45 58 M 21.8 8 140 80 100 T Gly/Trp 4 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 80 100 
46 55 M 23.4 6 150 90 110 T Gly/Gly 2 4 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 140 90 106.7 
47 50 M 23.5 10 140 90 106.7 T - 2 2 0 1 0 0 0 2 0 0 3 2 0 0 0 0 0 140 80 100 
48 60 M 22.8 8 150 100 116.7 T Gly/Gly 2 4 1 1 
1
0 
0 0 0 0 0 3 1 0 0 0 1 0 140 90 106.7 
49 48 M 21.9 1 150 90 110 T Gly/Gly 4 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 140 80 100 
50 43 M 19.6 8 140 80 100 T Gly/Gly 4 2 0 1 0 0 0 7 0 0 0 0 0 0 0 0 0 140 80 100 
51 60 M 20.8 12 160 100 120 T - 2 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 138 90 106 
52 55 M 26.4 10 150 90 110 T Gly/Trp 2 1 0 1 
1
0 
0 0 0 0 0 0 0 0 0 0 0 0 140 80 100 
53 55 M 24.3 6 136 84 101.3 C Gly/Gly 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
54 51 M 22.8 5 130 80 96.7 C - 0 2 1 0 2 0 0 0 0 0 2 1 0 0 0 0 0 130 80 96.7 
55 52 M 26.4 12 150 90 110 T Gly/Trp 2 2 0 1 4 0 0 0 0 0 3 0 2 0 1 0 0 140 90 106.7 
56 47 M 25.5 3 130 70 90 C - 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
57 54 M 24.8 8 130 80 96.7 C Gly/Gly 
 
0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
58 44 F 24.6 4 150 90 110 T Gly/Gly 2 2 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 140 90 106.7 
59 52 F 22.8 8 150 90 110 T Gly/Gly 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 140 86 104 
60 52 F 23.4 6 120 86 97.3 C Gly/Gly 2 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 86 100.7 
61 55 M 22.4 5 160 96 117.3 T Gly/Gly 2 2 0 1 2 0 0 0 0 0 2 1 0 0 0 0 0 154 90 111.3 
62 48 F 21.8 1 130 80 96.7 C - 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
63 50 M 19.8 4 130 70 90 C Gly/Gly 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
64 51 M 18.4 9 130 80 96.7 C - 2 0 0 0 4 0 0 0 0 0 2 0 1 0 0 0 0 130 80 96.7 
65 50 M 23.2 4 160 100 120 T Gly/Trp 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 150 90 110 
66 55 F 22.4 5 130 80 96.7 C - 2 0 0 0 2 0 0 0 0 0 2 2 0 0 0 0 0 130 80 96.7 
67 59 F 21.8 8 130 80 96.7 C Gly/Gly 2 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
68 52 F 24.8 2 150 96 114 T - 2 2 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 150 90 110 
69 55 F 26.8 5 140 100 113.3 T Gly/Gly 2 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
70 51 M 22.4 8 130 80 96.7 C - 4 4 0 0 8 0 0 0 0 0 3 0 1 0 0 0 0 130 80 96.7 
71 44 F 23.4 3 130 80 96.7 C Gly/Gly 1 0 0 0 6 0 0 0 0 0 2 2 0 0 0 0 0 130 80 96.7 
72 58 F 23.6 6 150 100 116.7 T - 2 2 0 1 2 0 0 0 0 0 2 0 0 0 1 0 0 150 90 110 
73 55 M 22.8 5 130 80 96.7 C - 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
74 54 M 25.8 3 140 100 113.3 T Gly/Gly 4 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 136 96 109.3 
75 56 M 26.3 8 130 86 100.7 C - 2 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 86 100.7 
76 51 M 26.4 6 140 90 106.7 T Gly/Trp 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 140 90 106.7 
77 56 M 23.4 7 150 100 116.7 T Gly/Gly 0 2 1 1 4 0 0 0 0 0 3 0 0 0 1 0 0 140 90 106.7 
78 55 M 24.8 5 130 80 96.7 C - 2 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
79 42 M 25.4 2 130 80 96.7 C Gly/Gly 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
80 45 M 26.4 2 180 100 126.7 T Gly/Gly 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 160 90 113.3 
81 40 M 23.8 2 130 80 96.7 C - 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
82 51 M 22.6 3 110 70 83.3 C Gly/Gly 0 2 0 0 8 0 0 0 0 0 3 2 0 0 0 0 0 120 80 93.3 
83 60 M 21.2 7 160 80 106.7 T Gly/Gly 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 146 80 102 
84 54 M 23.8 6 160 100 120 T Gly/Gly 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 140 90 106.7 
85 48 M 23.5 8 130 80 96.7 C Gly/Gly 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
86 59 M 24.6 11 130 70 90 C - 4 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
87 56 M 25.4 8 150 100 116.7 T Gly/Trp 2 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 150 90 110 
88 44 M 22.5 4 130 70 90 C - 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 140 80 100 
89 56 F 24.6 10 110 80 90 C Gly/Gly 2 4 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 120 80 93.3 
90 52 M 21 6 120 80 93.3 C - 4 0 0 0 4 0 0 0 0 0 2 0 0 0 1 0 0 120 80 93.3 
91 51 M 23.6 4 130 80 96.7 C Gly/Gly 4 2 0 0 4 0 0 0 0 0 2 0 2 0 0 0 0 130 80 96.7 
92 43 M 18.6 3 130 80 96.7 C Gly/Gly 2 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 130 80 96.7 
93 52 F 22.4 8 140 90 106.7 T Gly/Gly 2 1 0 1 2 0 0 0 0 0 2 0 0 0 0 0 0 140 90 106.7 
94 56 M 23.8 3 160 90 113.3 T Gly/Gly 4 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 154 88 110 
95 48 M 24.6 2 130 80 96.7 C - 4 4 0 0 2 0 0 0 0 0 2 0 0.5 0 0 0 0 130 80 96.7 
96 54 M 23.8 5 130 86 100.7 C - 2 4 0 0 6 0 0 0 0 0 3 2 0 0 1 0 0 130 80 96.7 
97 60 F 24.6 12 130 80 96.7 C - 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
98 57 M 26 7 150 90 110 T Gly/Trp 2 4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 146 90 108.7 
99 59 M 25.8 8 130 80 96.7 C Gly/Trp 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 130 80 96.7 
10
0 
60 M 22.6 10 120 80 93.3 C - 4 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 120 80 93.3 
 
ANNEXURE-2 
α-ADDUCIN POLYMORPHISM GENOTYPING – MATERIALS AND 
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Fig.2: 
Instruments needed 
for DNA extraction 
1. Water Bath
2. Vortex Shaker
3. Refrigerated 
centrifuge 
1. 2.
3.
 
 
 
Fig.1: (Clockwise from top left) Articles for DNA extraction – Lysis Buffer, Elution Buffer, 
Proteinase K; working rack for the processing with protocol pamphlet by the side, Micro 
pipettes, Blood samples collected in EDTA vaccutainers. 
  
1.
2.
3. 4.
 
 
Fig.3: (Clockwise from top left) : Laminar flow chamber for sterile work area, PCR Machine, 
Gel Electrophoresis visualization unit, PCR display screen with α-Adducin program settings.  
Fig.4: (1) Submarine type gel electrophoresis apparatus,  
(2) Cast gel after completion of electrophoresis,  
(3) Cast and Run Gel showing pink (Ethidium bromide) & blue (gel loading dye) 
indicator lines, 
 (4) Visualization of DNA bands with UV light. (Standardization done at 60ºC) 
PROFORMA        
    REF. NO: 
NAME:       AGE/SEX: 
CONTACT : 
 
HYPERTENSION  HISTORY: 
 DURATION: 
  CURRENT ANTIHYPERTENSIVE MEDICATION :  
    
 
 BP RECORDS OF PAST 3 MONTHS: 
   
 
PAST MEDICAL HISTORY: 
DM: 
LIVER DISEASE: 
RENAL DISEASE: 
ALLERGIES: 
PAST H/O SIGNIFICANT HOSPITALIZATION/ SURGERY: 
BASELINE INVESTIGATION: 
CBC LFT RFT Glycemic/Lipid 
Profile 
HB: S.Bil: Urea: RBS: 
TC: SGOT: Creat: T.Cholesterol: 
DC: SGPT: Na
+
:                 K
+
: Triglycerides: 
ESR: SAP:   
PLT: S.Protein:   
AVERAGE 3 MONTH BP VALUE : 
ALLOCATION : Control/Test 
IF TEST, T.HYDROCHLORTHIAZIDE 12.5mg OD *3months 
Drug Issue Date BP recording during 
visit 
Reported ADR Lab investigation 
1.   5ml of venous 
blood in EDTA 
vaccutainer for 
genotyping 
2.   - 
3.   Issue Lab slip 
4. End of study drug    Verify lab 
parameters 
FOLLOW-UP LAB INVESTIGATION: 
CBC LFT RFT Glycemic/Lipid 
Profile 
HB: S.Bil: Urea: RBS: 
TC: SGOT: Creat: T.Cholesterol: 
DC: SGPT: Na
+
:                 K
+
: Triglycerides: 
ESR: SAP:   
PLT: S.Protein:   
 
GENOTYPING RESULT: 
 
 
 
PATIENT INFORMATION SHEET - ந ோயோளி தகவல் தோள் 
 α Adducin (        )                      
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              .  
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                        .                        
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Hydrochlorthiazide                            
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            . 
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        .  
 
 
 
 
 
 
 
Patient Consent Form 
Study Title: A study to assess association of  α-Adducin polymorphism in essential hypertension and its 
impact on responsiveness to hydrochlorthiazide in patients attending hypertension clinic in a tertiary care 
hospital 
Study Center: Kilpauk Medical College, Chennai-10 
Patient Name:         O.P. No.: 
Patient Age/sex: 
I confirm that I have understood the purpose and procedure of the above study. I had the opportunity to 
ask questions and all my doubts have been answered satisfactorily.  
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without my legal rights being affected. 
I understand that the  members of the ethical committee and the investigator involved in the study will not 
need my permission to look at my health records, both in respect to the current study and any other 
further research that may be conducted in relation to it. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that may arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
withdrawal of 5ml of blood at the beginning and end of the study. 
Patient Signature/ Thumb Impression: 
Patient Name and address: 
 
Witness Signature/ Thumb Impression: 
Witness Name and address: 
Investigator’s Signature: 
Name of the Investigator: 
Place: 
Date: 
 
 
 
 
 
 
 
 
 
 
 
உயர் இரத்த அழுத்தம் ந ோயோளிகளுக்கு α- Adducin போலிமோர்பிஸம் மற்றும் அதன் கோரணமோக Hydrochlorthiazide 
மருந்து செயல்திறனுக்கு உள்ள மோற்றம் குறித்த ஆய்வு 
 
ANTI-PLAGIARISM REPORT GENERATED VIA TURNITIN 
 
 
 
ANNEXURE-IV 
APPROVAL CERTIFICATE FROM INSTITUTIONAL ETHICS COMMITTEE 
 
 
ANNEXURE -V 
